v3.26.1
Condensed Consolidated Statements of Operations - Unaudited - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Revenue $ 36,839 $ 0
Operating expenses:    
Research and development 8,978 2,830
General and administrative 4,598 3,673
Total operating expenses 13,576 6,503
Operating income (loss) 23,263 (6,503)
Interest income 838 331
Income (loss) before income taxes and noncontrolling interest 24,134 (6,217)
Income tax provision 0 0
Net income (loss) before noncontrolling interest 24,134 (6,217)
Less: net loss attributable to noncontrolling interest 0 (1,125)
Net income (loss) attributable to vTv Therapeutics Inc. 24,134 (5,092)
Net income (loss) attributable to vTv Therapeutics Inc. common shareholders 24,134 (5,092)
Nonrelated Party    
Operating expenses:    
Other income (expense), net 9 (17)
Related Party    
Operating expenses:    
Other income (expense), net $ 24 $ (28)
Class A Common Stock    
Operating expenses:    
Basic net income (loss) per share of vTv Therapeutics Inc. Class A common stock (in usd per share) $ 1.94 $ (0.77)
Basic weighted average number of vTv Therapeutics Inc. Class A common stock (in shares) 12,409,278 6,582,844
Diluted net income (loss) per share of vTv Therapeutics Inc. Class A common stock (in usd per share) $ 1.65 $ (0.77)
Diluted weighted average number of vTv Therapeutics Inc. Class A common stock (in shares) 14,634,420 6,582,844